Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 30 · below the Ichimoku cloud · RSI 44 · MACD below its signal
None of the 29 investors followed here reported a position in DOSE.CN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DOSE.CN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for DOSE.CN.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.5 | 3.4 | -26.7 | -13.6 | 15.8 | -4.5 | -9.5 | 26.3 | 8.3 | -30.8 | −30.8% | ||
| 2025 | -13.6 | -10.5 | 17.6 | 0.0 | 5.0 | -11.9 | 0.0 | -5.4 | -8.6 | 12.5 | -11.1 | -18.8 | −40.9% |
| 2024 | -3.0 | 9.4 | 2.9 | 30.6 | -6.4 | -18.2 | 5.6 | -18.4 | 9.7 | 58.8 | 3.7 | -21.4 | +33.3% |
| 2023 | 0.0 | 0.0 | 0.0 | 0.0 | 66.7 | -6.7 | 7.1 | -6.7 | -28.6 | 120.0 | -27.3 | 3.1 | +83.3% |
| 2022 | -43.3 | -13.6 | 15.7 | 1.7 | -30.0 | -9.5 | -42.1 | -18.2 | 0.0 | 0.0 | 0.0 | 0.0 | −82.7% |
| 2021 | -41.3 | 13.5 | 19.0 | -12.0 | -4.5 | 176.2 | 8.6 | -4.8 | 5.0 | -1.6 | -11.3 | -5.5 | +65.1% |
| 2020 | -13.2 | 4.5 | -44.9 | 21.1 | 8.7 | -16.0 | 66.7 | -5.7 | 0.0 | 0.0 | 3.0 | -7.4 | −17.1% |
| 2019 | -2.2 | -7.8 | -6.0 | -2.6 | 6.6 | -13.6 | 0.0 | 5.7 | 1.4 | -30.7 | -5.8 | -22.4 | −58.7% |
| 2018 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1126.7 | +1126.7% |
| 2017 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2016 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2015 | -80.0 | 0.0 | 0.0 | 0.0 | 300.0 | 75.0 | -71.4 | 0.0 | 200.0 | 0.0 | -50.0 | 0.0 | −40.0% |
| 2014 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2013 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -66.7 | 400.0 | 0.0 | 0.0 | 0.0 | +66.7% |
| 2012 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2011 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -75.0 | 0.0 | -25.0 | −81.2% |
| 2010 | 0.0 | -20.0 | -5.0 | 0.0 | 0.0 | 0.0 | 0.0 | -57.9 | 0.0 | 0.0 | −68.0% |
No analyst coverage for this instrument.
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system designed to rapidly release pharmaceuticals, emulsified oils, and over-the-counter medicines into the bloodstream. It also provides over-the-counter products consisting of QuickStrip Energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12; and QuickStrip Sleep to deliver melatonin, as well as dental products including Lidocaine QuickStrip, a muco-adhesive oral thin film. It also engages in the research, production, provision, and distribution of technical services for the delivery of oral thin film strips containing active ingredients. In addition, the company is involved in the sale of health and wellness products, such as nutraceuticals; white label manufacturing, including oral thin film strips containing active ingredients under cannabis licensing; and the provision of consulting services for the application of active ingredients with the oral thin film polymer formulation and processes. Rapid Dose Therapeutics Corp. is headquartered in Burlington, Canada.
No recent headlines.